Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 350

1.

[New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].

Moura B, Homicsko K, Berthod G, Cerottini JP, Guggisberg D, Gaide O, Maillard MH, Michielin O.

Rev Med Suisse. 2015 May 20;11(475):1108, 1110-4. Review. French.

PMID:
26152085
2.

[Melanoma: a new therapeutic era].

Berthod G, Homicsko K, Bouchaab H, Matter M, Cerottini JP, Guggisberg D, Speiser D, Leyvraz S, Michielin O.

Rev Med Suisse. 2011 May 25;7(296):1126-30. Review. French.

PMID:
21721201
3.

Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients.

Speiser DE, Schwarz K, Baumgaertner P, Manolova V, Devevre E, Sterry W, Walden P, Zippelius A, Conzett KB, Senti G, Voelter V, Cerottini JP, Guggisberg D, Willers J, Geldhof C, Romero P, Kündig T, Knuth A, Dummer R, Trefzer U, Bachmann MF.

J Immunother. 2010 Oct;33(8):848-58. doi: 10.1097/CJI.0b013e3181f1d614.

PMID:
20842051
4.

Enrichment of human CD4+ V(alpha)24/Vbeta11 invariant NKT cells in intrahepatic malignant tumors.

Bricard G, Cesson V, Devevre E, Bouzourene H, Barbey C, Rufer N, Im JS, Alves PM, Martinet O, Halkic N, Cerottini JC, Romero P, Porcelli SA, Macdonald HR, Speiser DE.

J Immunol. 2009 Apr 15;182(8):5140-51. doi: 10.4049/jimmunol.0711086.

5.

[New developments in cancer immunotherapy].

Michielin O, Rufer N, Romero P, Laurent J, Cerottini JP, Gugisberg D, Leyvraz S, Speiser D.

Rev Med Suisse. 2008 May 21;4(158):1248-51. Review. French.

PMID:
18616206
6.

Sentinel lymph node involvement and a high Breslow index are independent factors of risk for early relapse of melanoma.

Willi JP, Matter M, Buchegger F, Antonescu C, Guggisberg D, Cerottini JP, Krischer J, Braun R, Marie Kurt A, Roche B, Lemoine R, Rimoldi D, Lejeune FJ, Liénard D, Bischof Delaloye A.

Nuklearmedizin. 2007;46(6):244-51.

7.

The role of interval nodes in sentinel lymph node mapping and dissection for melanoma patients.

Matter M, Nicod Lalonde M, Allaoua M, Boubaker A, Liénard D, Gugerli O, Cerottini JP, Bouzourene H, Bischof Delaloye A, Lejeune F.

J Nucl Med. 2007 Oct;48(10):1607-13. Epub 2007 Sep 14.

8.

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.

J Immunother. 2007 Feb-Mar;30(2):240-50.

PMID:
17471171
9.

Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients.

Alves PM, Viatte S, Fagerberg T, Michielin O, Bricard G, Bouzourene H, Vuilleumier H, Kruger T, Givel JC, Lévy F, Speiser DE, Cerottini JC, Romero P.

Cancer Immunol Immunother. 2007 Nov;56(11):1795-805. Epub 2007 Apr 20.

PMID:
17447064
10.

IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.

Barbey C, Baumgaertner P, Devevre E, Rubio-Godoy V, Derre L, Bricard G, Guillaume P, Luescher IF, Liénard D, Cerottini JC, Romero P, Rufer N, Speiser DE.

J Immunol. 2007 Mar 15;178(6):3566-74.

11.

The human T cell response to melanoma antigens.

Romero P, Cerottini JC, Speiser DE.

Adv Immunol. 2006;92:187-224. Review.

PMID:
17145305
12.

Human effector CD8+ T lymphocytes express TLR3 as a functional coreceptor.

Tabiasco J, Devêvre E, Rufer N, Salaun B, Cerottini JC, Speiser D, Romero P.

J Immunol. 2006 Dec 15;177(12):8708-13.

13.

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.

Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P.

J Immunol. 2006 Nov 15;177(10):6769-79.

14.

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.

J Immunol. 2006 Aug 1;177(3):1670-8.

15.

A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination.

Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich PY, Rimoldi D, Liénard D, Cerottini JC, Romero P, Rufer N.

J Immunol. 2006 Jul 15;177(2):1338-48.

16.

Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide.

Appay V, Speiser DE, Rufer N, Reynard S, Barbey C, Cerottini JC, Leyvraz S, Pinilla C, Romero P.

Eur J Immunol. 2006 Jul;36(7):1805-14.

17.

Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells.

Batard P, Peterson DA, Devêvre E, Guillaume P, Cerottini JC, Rimoldi D, Speiser DE, Winther L, Romero P.

J Immunol Methods. 2006 Mar 20;310(1-2):136-48. Epub 2006 Feb 17.

PMID:
16516226
18.

Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex.

Pittet MJ, Gati A, Le Gal FA, Bioley G, Guillaume P, de Smedt M, Plum J, Speiser DE, Cerottini JC, Dietrich PY, Romero P, Zippelius A.

J Immunol. 2006 Feb 15;176(4):2330-6.

19.

Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.

Chapatte L, Colombetti S, Cerottini JC, Lévy F.

Cancer Res. 2006 Jan 15;66(2):1155-60.

20.

Structural prediction of peptides bound to MHC class I.

Fagerberg T, Cerottini JC, Michielin O.

J Mol Biol. 2006 Feb 17;356(2):521-46. Epub 2005 Dec 5.

PMID:
16368108
21.

On the significance of CD8 alpha alpha expression for T cell memory.

Romero P, Cerottini JC, Luescher I.

Eur J Immunol. 2005 Nov;35(11):3092-4.

22.

Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.

Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, Guillaume P, Cerottini JC, Romero P, Leyvraz S.

Clin Exp Immunol. 2005 Nov;142(2):292-302.

23.

Tinkering with nature: the tale of optimizing peptide based cancer vaccines.

Michielin O, Blanchet JS, Fagerberg T, Valmori D, Rubio-Godoy V, Speiser D, Ayyoub M, Alves P, Luescher I, Gairin JE, Cerottini JC, Romero P.

Cancer Treat Res. 2005;123:267-91. Review. No abstract available.

PMID:
16211875
24.

Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1.

Le Gal FA, Ayyoub M, Dutoit V, Widmer V, Jäger E, Cerottini JC, Dietrich PY, Valmori D.

J Immunother. 2005 May-Jun;28(3):252-7.

PMID:
15838382
25.

CD4+ T cell responses to SSX-4 in melanoma patients.

Ayyoub M, Merlo A, Hesdorffer CS, Rimoldi D, Speiser D, Cerottini JC, Chen YT, Old LJ, Stevanovic S, Valmori D.

J Immunol. 2005 Apr 15;174(8):5092-9.

26.

Tumor cell recognition efficiency by T cells.

Speiser DE, Cerottini JC, Romero P.

PLoS Med. 2005 Mar;2(3):e77; author reply e95. Epub 2005 Mar 29. No abstract available.

27.

Ubiquitylation of a melanosomal protein by HECT-E3 ligases serves as sorting signal for lysosomal degradation.

Lévy F, Muehlethaler K, Salvi S, Peitrequin AL, Lindholm CK, Cerottini JC, Rimoldi D.

Mol Biol Cell. 2005 Apr;16(4):1777-87. Epub 2005 Feb 9.

28.

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P.

J Clin Invest. 2005 Mar;115(3):739-46.

29.

Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.

Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE.

J Immunol. 2005 Feb 1;174(3):1709-16.

30.

Distinct but overlapping T helper epitopes in the 37-58 region of SSX-2.

Ayyoub M, Merlo A, Hesdorffer CS, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Chen YT, Old LJ, Stevanovic S, Valmori D.

Clin Immunol. 2005 Jan;114(1):70-8.

PMID:
15596411
31.

Recent advances in tumour antigen-specific therapy: in vivo veritas.

Mahnke YD, Speiser D, Luescher IF, Cerottini JC, Romero P.

Int J Cancer. 2005 Jan 10;113(2):173-8. Review.

32.

Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.

Speiser DE, Pittet MJ, Guillaume P, Lubenow N, Hoffman E, Cerottini JC, Romero P.

J Immunother. 2004 Jul-Aug;27(4):298-308.

PMID:
15235391
33.

Identification of an SSX-2 epitope presented by dendritic cells to circulating autologous CD4+ T cells.

Ayyoub M, Hesdorffer CS, Metthez G, Stevanovic S, Ritter G, Chen YT, Old LJ, Speiser D, Cerottini JC, Valmori D.

J Immunol. 2004 Jun 1;172(11):7206-11.

34.

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2004 May 19;4:4.

35.

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ.

Cancer Res. 2004 Apr 15;64(8):2865-73.

36.

An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR.

Ayyoub M, Hesdorffer CS, Montes M, Merlo A, Speiser D, Rimoldi D, Cerottini JC, Ritter G, Scanlan M, Old LJ, Valmori D.

J Clin Invest. 2004 Apr;113(8):1225-33.

37.

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Liénard D, Lejeune F, Cerottini JC, Romero P.

Semin Cancer Biol. 2003 Dec;13(6):461-72. Review.

PMID:
15001165
38.

Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues.

Zippelius A, Bioley G, Le Gal FA, Rufer N, Brandes M, Batard P, De Smedt M, Plum J, Speiser DE, Cerottini JC, Dietrich PY, Romero P, Pittet MJ.

J Immunol. 2004 Mar 1;172(5):2773-7.

39.

Monitoring tumor antigen specific T-cell responses in cancer patients and phase I clinical trials of peptide-based vaccination.

Romero P, Cerottini JC, Speiser DE.

Cancer Immunol Immunother. 2004 Mar;53(3):249-55. Epub 2003 Dec 24. Review.

PMID:
14704832
40.

Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2003 Oct 28;3:15.

41.

Lack of BRAF mutations in uveal melanoma.

Rimoldi D, Salvi S, Liénard D, Lejeune FJ, Speiser D, Zografos L, Cerottini JC.

Cancer Res. 2003 Sep 15;63(18):5712-5.

42.

Detection of micrometastases in sentinel lymph nodes from melanoma patients: direct comparison of multimarker molecular and immunopathological methods.

Rimoldi D, Lemoine R, Kurt AM, Salvi S, Berset M, Matter M, Roche B, Cerottini JP, Guggisberg D, Krischer J, Braun R, Willi JP, Antonescu C, Slosman D, Lejeune FJ, Liénard D; Groupe Mélanome Lémanique.

Melanoma Res. 2003 Oct;13(5):511-20.

PMID:
14512793
43.

Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.

Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini JC, Valmori D, Speiser D.

Cancer Res. 2003 Sep 1;63(17):5601-6.

44.

Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P.

Cancer Immun. 2003 Sep 9;3:12.

45.

Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells.

Pittet MJ, Rubio-Godoy V, Bioley G, Guillaume P, Batard P, Speiser D, Luescher I, Cerottini JC, Romero P, Zippelius A.

J Immunol. 2003 Aug 15;171(4):1844-9.

46.

Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions.

Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, Corthesy P, Cerottini JC, Leyvraz S, Roosnek E, Nabholz M, Romero P.

Blood. 2003 Sep 1;102(5):1779-87. Epub 2003 May 15.

47.

Redirecting anti-viral CTL against cancer cells by surface targeting of monomeric MHC class I-viral peptide conjugated to antibody fragments.

Robert B, Guillaume P, Luescher I, Doucey MA, Cerottini JC, Romero P, Mach JP.

Cancer Immun. 2001 Mar 30;1:2.

48.

Can hTERT peptide (540-548) -specific CD8 T cells recognize and kill tumor cells?

Speiser DE, Cerottini JC, Romero P.

Cancer Immun. 2002 Oct 14;2:14. Review.

49.
50.

Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.

Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, Cognet I, Widmer V, Walker PR, Michielin O, Guillaume P, Connerotte T, Jotereau F, Coulie PG, Romero P, Cerottini JC, Bonneville M, Valmori D.

J Immunol. 2003 May 15;170(10):5103-9.

Supplemental Content

Loading ...
Support Center